Fundraising Fox

1910

YC W19

Boston, US · Founded 2018 · 20 employees · 4 known investors

1910 develops an AI platform that integrates multimodal data, frontier AI models, and high-throughput lab automation to accelerate drug discovery and development for pharmaceutical companies. The platform targets undruggable targets and aims to improve R&D productivity in the biopharma industry.

Also known as 1910 Genetics

AI & Machine LearningBiotechDeep TechHealthtechAI-powered Drug DiscoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W19)

1910 was founded in 2018 by Jen Asher.

JAJen Asher
Jen Asherin𝕏Founder & CEOJen Asher is Founder and CEO of 1910, which develops an AI platform integrating multimodal data and lab automation to accelerate drug discovery for pharmaceutical companies.

Investors · 4

Y Combinator✓ verifiedSan Francisco · $500K
FoundersX Ventures✓ verifiedSilicon Valley
Playground Global✓ verifiedPalo Alto · $1M – $20M
Scientia VenturesNew York

Funding

SEC filings, press & company announcements

$3M disclosed across 1 round · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap
10x Genomics 1-color3 shared keywords10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.

Companies competing with 1910 for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Casa 1910 Announces $3M Funding | Cigar Journalcigarjournal.com · Sep 2025Casa 1910 AG Raises $3 Million, Realigns Pricing, and Expands Global Partnerships - Tobacco Reportertobaccoreporter.com · Sep 2025Casa 1910 AG Raises $3 Million, Drops Prices, Expands Distribution - Tobacco Reportertobaccoreporter.com · Sep 2025This Biotech Founder Wants to Use AI to Help Get Drugs to Market Faster | Inc.cominc.com · Mar 2024Microsoft and 1910 Genetics Partner to Build the Infrastructure Layer for Drug Discovery and Development Using AI and High-Performance Computing — 1910 Genetics1910genetics.com · Feb 20241910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain — 1910 Genetics1910genetics.com · Sep 20211910 Genetics Start-Up Raises $22M to Use AI to Accelerate Drug Discovery – Unite.AIunite.ai · Mar 20211910 Genetics Raises $26M in Seed and Series A Funding - FinSMEsfinsmes.com · Mar 2021

Frequently asked questions

What does 1910 do?
1910 develops an AI platform that integrates multimodal data, frontier AI models, and high-throughput lab automation to accelerate drug discovery and development for pharmaceutical companies. The platform targets undruggable targets and aims to improve R&D productivity in the biopharma industry.
Who founded 1910?
1910 was founded by Jen Asher in 2018.
Who are 1910's investors?
1910's investors include Y Combinator, FoundersX Ventures, Playground Global, Scientia Ventures.
How much funding has 1910 raised?
1910 has disclosed $3M raised across 1 round.
Where is 1910 headquartered?
1910 is headquartered in Boston, US.